Microcap Ledger X4 Pharmaceuticals, Inc $XFOR
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Boston, MA
- Fiscal year end
- December 31
- Shares outstanding
- 99,146,743 [10-Q 2026-08-06]
What the company doesAI summary of filing
X4 Pharmaceuticals is a biopharmaceutical company developing and commercializing therapeutics for rare hematology diseases. The company has one FDA-approved product, XOLREMDI (mavorixafor), an oral small-molecule CXCR4 antagonist approved in April 2024 for treating WHIM syndrome in patients 12 years and older; the company is not actively promoting XOLREMDI but maintains patient access through specialty pharmacy and international partners. The company generates revenue through product sales of XOLREMDI and from sublicense agreements, though it has not achieved significant revenue to date. X4 is primarily focused on advancing mavorixafor through a pivotal Phase 3 trial (4WARD) in chronic neutropenia patients, with enrollment targeted to complete in the third quarter of 2026 and top-line data expected in the second half of 2027. [10-K 2026-03-17]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $4.80M | −$36.40M | −$40.39M | $195.09M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | $6.50M | −$79.20M | −$85.62M | $217.05M | [10-K 2026-03-17] |
| FY ended Dec 2024 | $2.60M | −$37.45M | −$130.90M | $55.70M | [10-K 2026-03-17] |
- Quarterly cash burn
- −$20.19M
- Cash runway Estimate
- ~29 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-11 | 170,546,469 | [10-Q 2024-11-13] |
| 2025-03-20 | 173,662,376 | [10-K 2025-03-26] |
| 2025-04-28 | 5,788,686 | [10-Q 2025-05-01] |
| 2025-08-04 | 11,408,357 | [10-Q 2025-08-08] |
| 2025-10-31 | 87,436,688 | [10-Q 2025-11-05] |
| 2026-03-12 | 90,919,696 | [10-K 2026-03-17] |
| 2026-05-01 | 94,319,696 | [10-Q 2026-05-06] |
| 2026-07-31 | 99,146,743 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-05-06; declared effective 2026-05-14 [S-3 2026-05-06]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-01 | Kirske David | sell | 11,767 | $2.86 | [4 2026-10-05] |
| 2026-08-12 | Volpone John | sell | 24,576 | $4.44 | [4 2026-08-13] |
| 2026-08-12 | Craig Adam R | sell | 47,436 | $4.44 | [4 2026-08-13] |
| 2026-06-30 | Kirske David | sell | 8,543 | $4.26 | [4 2026-07-01] |
| 2026-05-12 | Kirske David | sell | 16,961 | $4.29 | [4 2026-05-13] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-08 | 8-K | Material agreement entered; Material agreement terminated; New financial obligation |
| 2026-10-07 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-09-21 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-09-09 | 8-K | Other events |
| 2026-09-08 | 8-K | Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-07-30 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-01 | 8-K | Director or officer change; Regulation FD disclosure |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 8-K | Director or officer change; Shareholder vote results |
Alerts for $XFOR
Email me when X4 Pharmaceuticals, Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.